Anticancer Vaccines

Veterinary Clinics of North America - Small Animal Practice

Volumn 37, Issue 6, 2007, Pages 1111-1119

  Bergman, Philip J ^a,b  

^a BrightHeart Veterinary Centers   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BACTERIAL ANTIGEN; BCG VACCINE; CANCER TESTIS ANTIGEN; CANCER VACCINE; CORYNEBACTERIUM PARVUM VACCINE; DNA VACCINE; IMIQUIMOD; LIPOSOME; LIVE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOPHENOL MONOOXYGENASE; MURAMYL TRIPEPTIDE; PHOSPHATIDYLETHANOLAMINE; PLASMID DNA; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 18; RECOMBINANT INTERLEUKIN 2; SALMONELLOSIS VACCINE; SUPERANTIGEN; T LYMPHOCYTE ANTIBODY; VIROTHERAPY AGENT;

ADAPTIVE IMMUNITY; ANGIOSARCOMA; ANIMAL DISEASE; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; BLADDER CARCINOMA; BOWEN DISEASE; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DOG DISEASE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; GENE OVEREXPRESSION; IMMUNOCOMPETENCE; INJECTION SITE PAIN; INNATE IMMUNITY; LIPOSOMAL GENE DELIVERY SYSTEM; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MINIMAL RESIDUAL DISEASE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ONCOLYTIC VIROTHERAPY; OSTEOSARCOMA; REVIEW; TUMOR IMMUNOLOGY; VITILIGO;

ANIMALS; CANCER VACCINES; NEOPLASMS;

HARNESS;

EID: 35348916569     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2007.06.005     Document Type: Review

References (52)

1. Bergman P.J. Biologic response modification. In: Rosenthal R.C. (Ed). Veterinary oncology secrets. 1st edition (2001), Hanley & Belfus, Inc., Philadelphia 79-82
2. Reilly R.T., Emens L.A., and Jaffee E.M. Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer?. Curr Opin Investig Drugs 2 1 (2001) 133-135
3. Smyth M.J., Godfrey D.I., and Trapani J.A. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2 4 (2001) 293-299
4. Wallace M.E., and Smyth M.J. The role of natural killer cells in tumor control-effectors and regulators of adaptive immunity. Springer Semin Immunopathol 27 1 (2005) 49-64
5. Catchpole B., Gould S.M., Kellett-Gregory L.M., et al. Immunosuppressive cytokines in the regional lymph node of a dog suffering from oral malignant melanoma. J Small Anim Pract 43 10 (2002) 464-467
6. Zagury D., and Gallo R.C. Anti-cytokine Ab immune therapy: present status and perspectives. Drug Discov Today 9 2 (2004) 72-81
7. Morse M.A., Mosca P.J., Clay T.M., et al. Dendritic cell maturation in active immunotherapy strategies. Expert Opin Biol Ther 2 1 (2002) 35-43
8. Yamaguchi T., and Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 16 2 (2006) 115-123
9. Biller B.J., Elmslie R.E., Burnett R.C., et al. Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer. Vet Immunol Immunopathol 116 1-2 (2007) 69-78
10. Richardson M.A., Ramirez T., Russell N.C., et al. Coley toxins immunotherapy: a retrospective review. Altern Ther Health Med 5 3 (1999) 42-47
11. Parodi A.L., Misdorp W., Mialot J.P., et al. Intratumoral BCG and Corynebacterium parvum therapy of canine mammary tumours before radical mastectomy. Cancer Immunol Immunother 15 3 (1983) 172-177
12. Bostock D.E., and Gorman N.T. Intravenous BCG therapy of mammary carcinoma in bitches after surgical excision of the primary tumour. Eur J Cancer 14 8 (1978) 879-883
13. vd Meijden A.P., Steerenberg P.A., de Jong W.H., et al. The effects of intravesical and intradermal application of a new B.C.G. on the dog bladder. Urol Res 14 4 (1986) 207-210
14. MacEwen E.G. Approaches to cancer therapy using biological response modifiers. Vet Clin North Am Small Anim Pract 15 3 (1985) 667-688
15. MacEwen E.G., Patnaik A.K., Harvey H.J., et al. Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Invest 4 5 (1986) 397-402
16. Thamm D.H., Kurzman I.D., King I., et al. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin Cancer Res 11 13 (2005) 4827-4834
17. Dow S.W., Elmslie R.E., Willson A.P., et al. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest 101 11 (1998) 2406-2414
18. Suter S.E., Chein M.B., von M., et al. In vitro canine distemper virus infection of canine lymphoid cells: a prelude to oncolytic therapy for lymphoma. Clin Cancer Res 11 4 (2005) 1579-1587
19. Le L.P., Rivera A.A., Glasgow J.N., et al. Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells. Gene Ther 13 5 (2006) 389-399
20. Hemminki A., Kanerva A., Kremer E.J., et al. A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther 7 2 (2003) 163-173
21. Hodes M.E., Morgan S., Hubbard J.D., et al. Tissue culture and animal studies with an oncolytic bovine enterovirus (bovine enterovirus 1). Cancer Res 33 10 (1973) 2408-2414
22. MacEwen E.G., Kurzman I.D., Vail D.M., et al. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clin Cancer Res 5 12 (1999) 4249-4258
23. Kurzman I.D., MacEwen E.G., Rosenthal R.C., et al. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res 1 12 (1995) 1595-1601
24. Vail D.M., MacEwen E.G., Kurzman I.D., et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clin Cancer Res 1 10 (1995) 1165-1170
25. Hogge G.S., Burkholder J.K., Culp J., et al. Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer. Hum Gene Ther 9 13 (1998) 1851-1861
26. Dow S., Elmslie R., Kurzman I., et al. Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases. Hum Gene Ther 16 8 (2005) 937-946
27. Khanna C., Anderson P.M., Hasz D.E., et al. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 79 7 (1997) 1409-1421
28. Akhtar N., Padilla M.L., Dickerson E.B., et al. Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model. Neoplasia 6 2 (2004) 106-116
29. Phillips B.S., Padilla M.L., Dickerson E.B., et al. Immunostimulatory effects of human recombinant interleukin-12 on peripheral blood mononuclear cells from normal dogs. Vet Immunol Immunopathol 70 3-4 (1999) 189-201
30. Siddiqui F., Li C.Y., Larue S.M., et al. A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas. Mol Cancer Ther 6 1 (2007) 380-389
31. Okano F., and Yamada K. Canine interleukin-18 induces apoptosis and enhances Fas ligand mRNA expression in a canine carcinoma cell line. Anticancer Res 20 5B (2000) 3411-3415
32. Kruth S.A. Biological response modifiers: interferons, interleukins, recombinant products, liposomal products. Vet Clin North Am Small Anim Pract 28 2 (1998) 269-295
33. Tateyama S., Priosoeryanto B.P., Yamaguchi R., et al. In vitro growth inhibition activities of recombinant feline interferon on all lines derived from canine tumours. Res Vet Sci 59 3 (1995) 275-277
34. Whitley E.M., Bird A.C., Zucker K.E., et al. Modulation by canine interferon-gamma of major histocompatibility complex and tumor-associated antigen expression in canine mammary tumor and melanoma cell lines. Anticancer Res 15 3 (1995) 923-929
35. Alexander A.N., Huelsmeyer M.K., Mitzey A., et al. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma. Cancer Immunol Immunother 55 4 (2006) 433-442
36. U'Ren L.W., Biller B.J., Elmslie R.E., et al. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. J Vet Intern Med 21 1 (2007) 113-120
37. Hogge G.S., Burkholder J.K., Culp J., et al. Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogs. Cancer Gene Ther 6 1 (1999) 26-36
38. Quintin-Colonna F., Devauchelle P., Fradelizi D., et al. Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2. Gene Ther 3 12 (1996) 1104-1112
39. Jourdier T.M., Moste C., Bonnet M.C., et al. Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2). Gene Ther 10 26 (2003) 2126-2132
40. Milner R.J., Salute M., Crawford C., et al. The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine. Vet Immunol Immunopathol 114 3-4 (2006) 273-284
41. Gyorffy S., Rodriguez-Lecompte J.C., Woods J.P., et al. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen. J Vet Intern Med 19 1 (2005) 56-63
42. Helfand S.C., Soergel S.A., Donner R.L., et al. Potential to involve multiple effector cells with human recombinant interleukin-2 and antiganglioside monoclonal antibodies in a canine malignant melanoma immunotherapy model. J Immunother Emphasis Tumor Immunol 16 3 (1994) 188-197
43. Jeglum K.A. Chemoimmunotherapy of canine lymphoma with adjuvant canine monoclonal antibody 231. Vet Clin North Am Small Anim Pract 26 1 (1996) 73-85
44. Bergman P.J., Camps-Palau M.A., McKnight J.A., et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 24 21 (2006) 4582-4585
45. Bergman P.J., McKnight J., Novosad A., et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 9 4 (2003) 1284-1290
46. Srinivasan R., and Wolchok J.D. Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines. J Transl Med 2 1 (2004) 12-24
47. Liao J.C., Gregor P., Wolchok J.D., et al. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun 6 (2006) 8-18
48. Palomba M.L., Roberts W.K., Dao T., et al. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clin Cancer Res 11 1 (2005) 370-379
49. Peggs K.S., Quezada S.A., Korman A.J., et al. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 18 2 (2006) 206-213
50. Walter C.U., Biller B.J., Lana S.E., et al. Effects of chemotherapy on immune responses in dogs with cancer. J Vet Intern Med 20 2 (2006) 342-347
51. Emens L.A., and Jaffee E.M. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 65 18 (2005) 8059-8064
52. MacEwen E.G. An immunologic approach to the treatment of cancer. Vet Clin North Am 7 1 (1977) 65-75